Connecting the brain and new drug targets for schizophrenia

Whalley, H., Steele, J., Mukherjee, P., Romaniuk, L., McIntosh, A., Hall, Jeremy ORCID: https://orcid.org/0000-0003-2737-9009 and Lawrie, S. 2009. Connecting the brain and new drug targets for schizophrenia. Current Pharmaceutical Design 15 (22) , pp. 2615-2631. 10.2174/138161209788957500

Full text not available from this repository.

Abstract

One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Bentham Science Publishers
ISSN:	1381-6128
Last Modified:	31 Oct 2022 09:32
URI:	https://orca.cardiff.ac.uk/id/eprint/81476

Citation Data

Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item